Featured post

SCS research and awards news

For all our research and awards news, please visit our news page.

Showing posts with label Sumita Ratnasingam. Show all posts
Showing posts with label Sumita Ratnasingam. Show all posts

Monday, 19 December 2016

Monash Haematology research recognised at HAA

Associate Professor Wood
delivering the Ruth Sanger Oration
Research at Monash Haematology was recognised and awarded at the HAA Annual Scientific Meeting in Melbourne last month, attended by around 1500 national and international delegates.

The event is the combined scientific meeting of the Haematology Society of Australia and New Zealand (HSANZ), Australian and New Zealand Society of Blood Transfusion (ANZSBT) and the Australasian Society of Thrombosis and Haemostasis.

The prestigious Ruth Sanger Oration was awarded to Associate Professor Erica Wood, Monash Health haematologist and Head of Monash University’s Transfusion Research Unit. The award is the highest honour of the ANZSBT made in recognition of a significant contribution to the field of transfusion medicine.

Associate Professor Wood was recognised for her research, teaching, service to the ANZSBT and international work.

“It was a great honour to receive the award and deliver the Ruth Sanger Oration,” said Associate Professor Wood.  “My oration focussed on the role of haemovigilance systems in improving the safety of clinical transfusion in our region and internationally.”

“While our blood supplies in Australia and New Zealand are very safe, we still have a lot of work to do about how we use blood in our hospitals – human error is responsible for many of the serious adverse events related to transfusion,” said Associate Professor Wood.

Associate Professor Wood is a member of the World Health Organization expert advisory panel on transfusion medicine, Vice-President of the International Society of Blood Transfusion, and President of the International Haemovigilance Network. In these roles she has worked for more than 20 years to improve blood safety nationally and internationally. 

“We are privileged to have a transfusion expert of Associate Professor Wood’s calibre and international reputation championing patient blood management at Monash Health,” said Associate Professor Jake Shortt, Group leader at the Monash Health Translation Precinct.

Monash Health haematologist and Monash University PhD student Dr Ashwini Bennett received the HSANZ New Investigator scholarship. This highly competitive award of $60,000 enables Dr Bennett to continue her PhD at Monash Health and Monash University, where she is investigating novel markers of thrombosis.

Other recognition included an oral presentation by Monash Health haematologist Dr Sumita Ratnasingam, whose research focuses on mantle cell lymphoma (MCL).

Dr Ratnasingam’s study compared the safety and efficacy of first line immunochemotherapy (ICT) regimens in treating elderly patients with MCL.

“MCL accounts for 6% of all non-Hodgkin lymphoma and is a fairly aggressive disease with an expected survival of less than five years,” said Dr Ratnasingam.

“Despite the median age of diagnosis being 60-70 years, there is a paucity of treatment guidelines or clinical trials for elderly MCL to guide our management, resulting in varied treatment strategies and outcomes.”

Dr Ratnasingam undertook a retrospective audit of elderly MCL (elderly defined as age 60 or above) patients in four Victorian tertiary hospitals. The results confirm that typical older patients with MCL benefit from the same therapies normally reserved for younger patients.

Monash clinicians and researchers had 20 abstracts accepted for oral and poster presentations at the Annual Scientific Meeting.    

Monash University’s Adjunct Clinical Associate Professor Stephen Opat is the current President of the HSANZ and was the convenor of the meeting and chair of the local organising committee with many other Monash Haematology staff members, including Associate Professor Shortt, Associate Professor Wood and Dr Zane Kaplan.

An overview of Associate Professor Wood’s lecture can be found here: http://thelimbic.com/haematology/clinical-transfusion-practice-in-australia-could-be-safer-sanger-oration


Monday, 21 December 2015

Monash haematology research showcased at ASH Scientific Meeting in North America

Dr Sumita Ratnasingam with poster at
the ASH in Orlando, Florida.
An abstract presented by Monash Haematology Research Fellow Dr Sumita Ratnasingam at the American Society of Haematology (ASH) Scientific Meeting in Orlando, Florida last week has been selected for the "2016 Highlights of ASH in North America".

Published this month in Blood, the abstract Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression, is a collaborative research study led by Monash researchers including Dr Rathasingam, Associate Professor Stephen Opat and Associate Professor Jake Shortt.  Other contributors included collaborating clinicians from the Alfred, Monash and Peninsula Health.

“The authors describe the first case series of bortezomib use in autoimmune hematological disease,” said co-author Associate Professor Shortt.
“Building on an initial case from Monash Health that was reported in the New England Journal of Medicine (Shortt et al, NEJM, 2013; 368: 90-2), the anti-cancer drug bortezomib has now been successfully repurposed in a range of non-malignant immune-mediated diseases.”

Bortezomib was designed to kill myeloma cells—these arise from the part of the immune system that makes antibodies.

In autoimmune disease, antibodies from non-cancerous plasma cells are produced and these can attack normal tissues, including blood cells.

“On this basis, we have now used bortezomib ‘off-label’ to reduce antibody production in autoimmune disease, and it appears to be both effective and well tolerated,” added Associate Professor Shortt.

The novelty of this work merited selection showcasing in the ‘Highlights of ASH in North America, 2016’ program, which provides a re-cap of ‘stand out’ abstracts from the ASH meeting.

Investigators at Monash Haematology and the School of Clinical Sciences at Monash Health are currently developing a trial protocol in which to formally test this approach prospectively in patients.